江苏康宁杰瑞生物制药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO 2023-10-24 08:41
Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting 2023-08-10 09:02
Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting 2023-06-06 09:06
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE 2023-05-09 10:00
Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023 2023-04-17 14:01
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003 2023-03-16 09:58
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023 2023-03-15 10:06
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022 2022-12-12 15:51
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022 2022-12-12 15:00
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022 2022-12-12 10:33
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology 2022-11-22 09:18
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022 2022-09-14 09:11
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022 2022-09-14 09:04
Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ) 2022-09-14 09:01
First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer 2022-08-09 11:18
Alphamab Oncology Announced First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052 2022-06-14 08:58
Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO 2022-06-06 10:49
Research Updates on KN046 Presented at 2022 ASCO 2022-06-06 09:47
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights 2022-03-30 10:36
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights 2022-03-30 10:35
1 2 3 4